Sharon X Xie

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/12008725/publications.pdf

Version: 2024-02-01

52 papers	6,979 citations	101543 36 h-index	175258 52 g-index
53 all docs	53 docs citations	53 times ranked	8861 citing authors

#	Article	IF	Citations
1	Contribution of cerebrovascular disease in autopsy confirmed neurodegenerative disease cases in the National Alzheimerâ€™s Coordinating Centre. Brain, 2013, 136, 2697-2706.	7.6	609
2	Neurodegenerative disease concomitant proteinopathies are prevalent, age-related and APOE4-associated. Brain, 2018, 141, 2181-2193.	7.6	448
3	Neuropathologic substrates of Parkinson disease dementia. Annals of Neurology, 2012, 72, 587-598.	5.3	401
4	Neuropathological and genetic correlates of survival and dementia onset in synucleinopathies: a retrospective analysis. Lancet Neurology, The, 2017, 16, 55-65.	10.2	394
5	Co-morbidity of TDP-43 proteinopathy in Lewy body related diseases. Acta Neuropathologica, 2007, 114, 221-229.	7.7	378
6	Microtubule-binding drugs offset tau sequestration by stabilizing microtubules and reversing fast axonal transport deficits in a tauopathy model. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 227-231.	7.1	374
7	The Microtubule-Stabilizing Agent, Epothilone D, Reduces Axonal Dysfunction, Neurotoxicity, Cognitive Deficits, and Alzheimer-Like Pathology in an Interventional Study with Aged Tau Transgenic Mice. Journal of Neuroscience, 2012, 32, 3601-3611.	3.6	325
8	Questionnaire for impulsiveâ€compulsive disorders in Parkinson's Diseaseâ€“Rating Scale. Movement Disorders, 2012, 27, 242-247.	3.9	263
9	Epothilone D Improves Microtubule Density, Axonal Integrity, and Cognition in a Transgenic Mouse Model of Tauopathy. Journal of Neuroscience, 2010, 30, 13861-13866.	3.6	256
10	Evidence of Multisystem Disorder in Whole-Brain Map of Pathological TDP-43 in Amyotrophic Lateral Sclerosis. Archives of Neurology, 2008, 65, 636-41.	4.5	251
11	Clinical and Pathological Continuum of Multisystem TDP-43 Proteinopathies. Archives of Neurology, 2009, 66, 180-9.	4.5	232
12	Cerebrovascular atherosclerosis correlates with Alzheimer pathology in neurodegenerative dementias. Brain, 2012, 135, 3749-3756.	7.6	228
13	Acetylated tau, a novel pathological signature in Alzheimer's disease and other tauopathies. Brain, 2012, 135, 807-818.	7.6	226
14	Distribution patterns of tau pathology in progressive supranuclear palsy. Acta Neuropathologica, 2020, 140, 99-119.	7.7	210
15	Longitudinal study of normal cognition in Parkinson disease. Neurology, 2015, 85, 1276-1282.	1.1	197
16	Neurodegeneration Across Stages of Cognitive Decline in Parkinson Disease. Archives of Neurology, 2011, 68, 1562.	4.5	180
17	A platform for discovery: The University of Pennsylvania Integrated Neurodegenerative Disease Biobank. Alzheimer's and Dementia, 2014, 10, 477.	0.8	167
18	CSF biomarkers cutoffs: the importance of coincident neuropathological diseases. Acta Neuropathologica, 2012, 124, 23-35.	7.7	161

#	Article	IF	Citations
19	Alzheimer's disease pattern of brain atrophy predicts cognitive decline in Parkinson's disease. Brain, 2012, 135, 170-180.	7.6	149
20	Microglial activation and TDP-43 pathology correlate with executive dysfunction in amyotrophic lateral sclerosis. Acta Neuropathologica, 2012, 123, 395-407.	7.7	104
21	Evaluating the Patterns of Aging-Related Tau Astrogliopathy Unravels Novel Insights Into Brain Aging and Neurodegenerative Diseases. Journal of Neuropathology and Experimental Neurology, 2017, 76, 270-288.	1.7	98
22	Pathological 43-kDa Transactivation Response DNA-Binding Protein in Older Adults With and Without Severe Mental Illness. Archives of Neurology, 2010, 67, 1238-50.	4.5	90
23	Cognitive and Pathological Influences of Tau Pathology in Lewy Body Disorders. Annals of Neurology, 2019, 85, 259-271.	5.3	88
24	The development and convergence of co-pathologies in Alzheimerâ€™s disease. Brain, 2021, 144, 953-962.	7.6	76
25	Naltrexone for impulse control disorders in Parkinson disease. Neurology, 2014, 83, 826-833.	1.1	74
26	CSF tau and Î²-amyloid predict cerebral synucleinopathy in autopsied Lewy body disorders. Neurology, 2018, 90, e1038-e1046.	1.1	68
27	Correlating Cognitive Decline with White Matter Lesion and Brain Atrophy Magnetic Resonance Imaging Measurements inÂAlzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2015, 48, 987-994.	2.6	67
28	Semi-automated quantification of C9orf72 expansion size reveals inverse correlation between hexanucleotide repeat number and disease duration in frontotemporal degeneration. Acta Neuropathologica, 2015, 130, 363-372.	7.7	65
29	Building an integrated neurodegenerative disease database at an academic health center. Alzheimer's and Dementia, 2011, 7, e84-93.	0.8	63
30	CSF Apo-E levels associate with cognitive decline and MRI changes. Acta Neuropathologica, 2014, 127, 621-632.	7.7	60
31	Motor neuron disease clinically limited to the lower motor neuron is a diffuse TDP-43 proteinopathy. Acta Neuropathologica, 2011, 121, 509-517.	7.7	52
32	TMEM106B Effect on cognition in Parkinson disease and frontotemporal dementia. Annals of Neurology, 2019, 85, 801-811.	5.3	52
33	Ante mortem cerebrospinal fluid tau levels correlate with postmortem tau pathology in frontotemporal lobar degeneration. Annals of Neurology, 2017, 82, 247-258.	5.3	51
34	Comparative survey of the topographical distribution of signature molecular lesions in major neurodegenerative diseases. Journal of Comparative Neurology, 2013, 521, 4339-4355.	1.6	47
35	Limbic-predominant age-related TDP-43 encephalopathy differs from frontotemporal lobar degeneration. Brain, 2020, 143, 2844-2857.	7.6	44
36	The Penn Parkinson's Daily Activities Questionnaire-15: Psychometric properties of a brief assessment of cognitive instrumental activities of daily living in Parkinson's disease. Parkinsonism and Related Disorders, 2016, 25, 21-26.	2.2	42

#	Article	IF	Citations
37	APOE, thought disorder, and SPAREâ€AD predict cognitive decline in established Parkinson's disease. Movement Disorders, 2018, 33, 289-297.	3.9	35
38	Primary Tau Pathology, Not Copathology, Correlates With Clinical Symptoms in PSP and CBD. Journal of Neuropathology and Experimental Neurology, 2020, 79, 296-304.	1.7	35
39	Tau deposition patterns are associated with functional connectivity in primary tauopathies. Nature Communications, 2022, 13, 1362.	12.8	34
40	Regional brain amyloid-Î² accumulation associates with domain-specific cognitive performance in Parkinson disease without dementia. PLoS ONE, 2017, 12, e0177924.	2.5	33
41	Rate of Decline in Alzheimer Disease Measured by a Dementia Severity Rating Scale. Alzheimer Disease and Associated Disorders, 2009, 23, 268-274.	1.3	32
42	Subjective Cognitive Complaint in Parkinson's Disease Patients With Normal Cognition: Canary in the Coal Mine?. Movement Disorders, 2020, 35, 1618-1625.	3.9	31
43	Distinct characteristics of limbic-predominant age-related TDP-43 encephalopathy in Lewy body disease. Acta Neuropathologica, 2022, 143, 15-31.	7.7	29
44	Amyloidâ€Beta Positron Emission Tomography Imaging of Alzheimer's Pathology in Parkinson's Disease Dementia. Movement Disorders Clinical Practice, 2016, 3, 367-375.	1.5	28
45	An Alzheimerâ€™s Disease-Derived Biomarker Signature Identifies Parkinsonâ€™s Disease Patients with Dementia. PLoS ONE, 2016, 11, e0147319.	2.5	25
46	Longitudinal patterns of semantic and episodic memory in frontotemporal lobar degeneration and Alzheimerâ€™s disease. Journal of the International Neuropsychological Society, 2010, 16, 278-286.	1.8	21
47	Neuropsychological Subgroups in Non-Demented Parkinsonâ€™s Disease: A Latent Class Analysis. Journal of Parkinson's Disease, 2017, 7, 385-395.	2.8	21
48	Development and initial testing of the Penn Parkinson's Daily Activities Questionnaire. Movement Disorders, 2016, 31, 126-134.	3.9	20
49	Simulated brain biopsy for diagnosing neurodegeneration using autopsy-confirmed cases. Acta Neuropathologica, 2011, 122, 737-745.	7.7	15
50	Research consent capacity varies with executive function and memory in Parkinson's disease. Movement Disorders, 2016, 31, 414-417.	3.9	12
51	Signature laminar distributions of pathology in frontotemporal lobar degeneration. Acta Neuropathologica, 2022, 143, 363-382.	7.7	12
52	Trends in oral anticoagulant co-prescription with antiepileptic drugs among adults with epilepsy, 2010â€“2018. Epilepsy and Behavior, 2020, 113, 107550.	1.7	4